E
PRAX icon

Ergoteles’s Praxis Precision Medicines PRAX Stock Holding History

Ergoteles’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,011
Closed -$17.4K – 638
2023
Q2 		$17.4K Buy
+1,011
New +$15.5K ﹤0.01% 991
2022
Q4 		– Sell
-2,432
Closed -$83K – 1793
2022
Q3 		$83K Buy
+2,432
New +$121K ﹤0.01% 1403

Other funds holding PRAX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Ergoteles's PRAX Position: Q3 2023 in Review

Ergoteles sold out of Praxis Precision Medicines (PRAX) in Q3 2023, closing a stake of 1,011 shares — an estimated $17.4K sold.

Ergoteles first reported a position in PRAX in Q3 2022 and held it in 2 quarters. The position peaked at $83K in Q3 2022. 74 funds tracked by Wall St. Rank hold PRAX as of Q3 2023.

  • Ergoteles reported no remaining Praxis Precision Medicines position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 1,011 Praxis Precision Medicines shares in Q3 2023, an estimated $17.4K.
  • Ergoteles first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 2 quarters.
  • Ergoteles's Praxis Precision Medicines position peaked at $83K in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.